Featured Clinical Trials

[email protected]

LISCA-Lung1 is a clinical trial that is exploring whether an investigational medication called alisertib is effective in treating patients with pathologically confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and an anti-PD-L1 immunotherapy agent. 

Who can participate?

• Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy.
• Eligible patients must be at least 18 years old and cannot have used an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting.
• There are additional inclusion and exclusion criteria.  The investigator at the study center will determine if you meet all of the criteria.
   

Phone: 855-907-3286

The purpose of the study is to compare the efficacy and safety of BMS-986489 (anti-fucosyl-GM1+ nivolumab fixed-dose combination) in combination with carboplatin plus etoposide to that of atezolizumab with carboplatin plus etoposide as first-line therapy in adult participants with extensive-stage small cell lung cancer.

Who can participate?

• Participants must be healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
• Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system.

Those interested should contact the participating site nearest them for more details. A list of sites is located on the trial's ct.gov listing.

About the trial:

S1900K: A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

The trial is set up to find out if treating people with both tepotinib and ramucirumab — instead of only tepotinib — can lower the chance that the cancer will grow or spread. It's also testing whether this drug combination can lower the chance that people will develop swelling in their arms and legs as a side effect from tepotinib.

Who can participate:

This study is open to patients who were diagnosed with stage IV non-small cell lung cancer (NSCLC). It tests treatment for people whose NSCLC has a MET exon 14 skipping gene change (alteration). The study is not for people were already treated with:
•       Tepotinib or other drugs that target MET gene changes
•       Ramucirumab or similar drugs
 

Those interested should contact the participating site nearest them for more details. A list of sites is located on the trial's ct.gov listing.

About the trial:

S1900J: A Phase II Study of Amivantamab SC (Subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

The trial is set up to find out if a drug called amivantamab SC can shrink the cancer and lower the chance that the cancer will grow or spread. Everyone in the trial will receive amivantamab SC.

Who can participate:

This study is open to patients who were diagnosed with stage IV non-small cell lung cancer (NSCLC). It tests treatment for people with NSCLC that has extra copies of the MET gene (MET amplification). The study is specifically for people whose cancer got worse after earlier treatment — but not for people who have already received a drug that targets the MET gene (like tepotinib, capmatinib, or crizotinib).

Those interested should contact the participating site nearest them for more details. A list of sites is located on the trial's ct.gov listing.

About the trial:

S1900G: A Randomized Phase II Study of Capmatinib (Tabrecta) plus Osimertinib (Tagrisso) with or without Ramucirumab (Cyramza) in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

The trial is set up to find out if adding the drug ramucirumab to 2 other drugs — osimertinib and capmatinib — lowers the chance that the cancer will spread or get worse. Osimertinib targets EGFR gene changes, capmatinib targets MET gene changes, and ramucirumab blocks tumors from forming new blood vessels (pathways that carry blood to the tumors).

Who can participate:

This study is open to patients who were diagnosed with stage IV non-small cell lung cancer. It tests targeted treatments for people with advanced non-small cell lung cancer that has certain changes (mutations) in both the EGFR and MET genes. The study is specifically for people whose cancer got worse after they took osimertinib.

Call 855-907-3286 or email [email protected] to learn more about this trial.

About the trial:

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation (KRYSTAL-7)

KRYSTAL-7 is a combined phase 2 and phase 3 clinical trial. We are recruiting for the phase 3 part of the trial that is testing if giving a drug called adagrasib with standard of care pembrolizumab can improve outcomes compared to giving pembrolizumab alone in patients with previously untreated advanced NSCLC who are known to have the KRAS G12C mutation and a PD-L1 score ≥ 50%.

Adagrasib is a targeted inhibitor of the KRAS G12C mutation that is approved in some countries for treating NSCLC as a standalone treatment after the cancer spreads or grows during treatment with standard of care therapy.

The phase 3 part of KRYSTAL-7 study is now actively enrolling eligible patients.

Who can participate:

• Participants must be 18 years or older.
• Participants must have a specific type of lung cancer known as NSCLC. This can be either squamous or non-squamous NSCLC.
• The cancer must have a specific genetic mutation called KRAS G12C.
• PD-L1 status: Participants’ tumors must have a high level of a protein called PD-L1, with a score of 50% or higher. This means that at least 50% of the cancer cells in the tumor exhibit this protein.
• The cancer must be unresectable (cannot be removed by surgery) and either locally advanced or metastatic (spread to other parts of the body).
• Participants should be receiving their first treatment for this stage of cancer.
• Identification of genetic mutation and protein level: The presence of the KRAS G12C mutation and PD-L1 level must be determined using specific tests approved by the study sponsor.
• Participants need to be in relatively good health, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. This status measures how well patients can perform daily activities.

You can enter your location to see the nearest recruiting trial site location through this link: www.BMSClinicalTrials.com/KRYSTAL-7

Your study-related costs will be covered, including visits, laboratory tests, and procedures. You may also be eligible for reimbursement for your travel or transportation.